Blurbs

Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX) and Zynerba Pharmaceuticals (ZYNE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Chimerix (CMRXResearch Report) and Zynerba Pharmaceuticals (ZYNEResearch Report).

Chimerix (CMRX)

H.C. Wainwright analyst Edward White maintained a Buy rating on Chimerix today and set a price target of $24.00. The company’s shares closed last Tuesday at $5.62, close to its 52-week low of $4.75.

According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of -5.5% and a 29.6% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Chimerix with a $20.00 average price target, implying a 247.8% upside from current levels. In a report released today, JonesTrading also reiterated a Buy rating on the stock with a $14.00 price target.

See the top stocks recommended by analysts >>

Zynerba Pharmaceuticals (ZYNE)

In a report released today, Serge Belanger from Needham maintained a Hold rating on Zynerba Pharmaceuticals. The company’s shares closed last Tuesday at $2.17, equals to its 52-week low of $2.17.

According to TipRanks.com, Belanger is a 3-star analyst with an average return of 2.6% and a 42.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Collegium Pharmaceutical, and Phasebio Pharmaceuticals.

Currently, the analyst consensus on Zynerba Pharmaceuticals is a Moderate Buy with an average price target of $8.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CMRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos